Client is a biopharmaceutical company that develops medicines in areas of unmet need.
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
BUD - Budget/Appropriations HCR - Health Issues MMM - Medicare/Medicaid
136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
THE MCMANUS GROUP
610 10th St. NW, Suite 300, Washington, DC, 20001, US
BARRETT THORNHILL JOHN MCMANUS BARRETT THORNHILL JOHN MCMANUS BARRETT THORNHILL JOHN MCMANUS